Traditional insulin replacement therapy involves multiple daily insulin injections or the delivery of insulin by a pump, the need for careful blood glucose monitoring, and the fear of an unwanted fall in blood glucose (hypoglycemia). Fear of hypoglycemia prevents optimal glycemic management leading to long-term hyperglycemia and damage to the body (kidney, heart, extremities).

Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management.

ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.

Biotechnology

Health Care

Life Sciences

Abvance Therapeutics

The Reno office likely serves as a strategic hub for executive leadership and high-level decision-making.

Abvance Therapeutics

Org chart

Teams

Offices

Abvance Therapeutics

Org chart

Teams

Offices

Related companies